Iovance Biotherapeutics (NASDAQ:IOVA – Free Report) had its price objective cut by Barclays from $40.00 to $18.00 in a report published on Monday, Marketbeat.com reports. They currently have an overweight rating on the biotechnology company’s stock. Other equities analysts have also issued research reports about the stock. Chardan Capital restated a buy rating and set […]
Harbor Capital Advisors Inc. Boosts Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
GEN. ROBERT D. RUSS, TAC COMMANDER dailypress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypress.com Daily Mail and Mail on Sunday newspapers.
TD Asset Management Inc. boosted its stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Rating) by 16.0% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 160,968 shares of the biotechnology company’s stock after purchasing an additional 22,244 shares during the quarter. TD Asset Management […]
pgyanke freerepublic.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from freerepublic.com Daily Mail and Mail on Sunday newspapers.